About Summit Therapeutics PLC (LON:SUMM)
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:SUMM
- CUSIP: N/A
- Web: www.summitplc.com/
Capitalization:- Market Cap: £113.02 million
- Outstanding Shares: 61,927,000
Average Prices:- 50 Day Moving Avg: GBX 197.43
- 200 Day Moving Avg: GBX 187.88
- 52 Week Range: GBX 138.14 - GBX 269.70
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: £22.98 million
- Price / Sales: 4.92
- Book Value: GBX 0.06 per share
- Price / Book: 30.42
Profitability:- EBITDA: ($7,170,000.00)
- Net Margins: 57.62%
- Return on Assets: 121.57%
Misc:- Average Volume: 31,720 shs.
Frequently Asked Questions for Summit Therapeutics PLC (LON:SUMM)
What is Summit Therapeutics PLC's stock symbol?
Summit Therapeutics PLC trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."
Who are some of Summit Therapeutics PLC's key competitors?
Some companies that are related to Summit Therapeutics PLC include Pieris Pharmaceuticals (PIRS), Kindred Biosciences (KIN), Endocyte (ECYT), Sorrento Therapeutics (SRNE), Cascadian Therapeutics (CASC), Spring Bank Pharmaceuticals (SBPH), Mast Therapeutics (SVRA), OncoCyte Corp (OCX), Clearside Biomedical (CLSD), Aileron Therapeutics (ALRN), Tocagen (TOCA), Ovid Therapeutc (OVID), Fate Therapeutics (FATE), Recro Pharma (REPH), Agile Therapeutics (AGRX), Vascular Biogenics (VBLT), Summit Therapeutics PLC (SMMT) and Redhill Biopharma (RDHL).
Who are Summit Therapeutics PLC's key executives?
Summit Therapeutics PLC's management team includes the folowing people:
- Glyn Edwards, Chief Executive Officer, Executive Director
- Erik Ostrowski, Chief Financial Officer
- David Roblin, Chief Operating Officer, President - Research and Development
- Ralf H. Rosskamp M.D., Chief Medical Officer
- Frank Murdoch Armstrong, Non-Executive Chairman of the Board
- Valerie L. Andrews, Non-Executive Director
- Stephen J. Davies, Non-Executive Director
- Barry J. Price Ph.D., Non-Executive Director
- David Wurzer CPA, Non-Executive Director
How do I buy Summit Therapeutics PLC stock?
Shares of Summit Therapeutics PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Summit Therapeutics PLC's stock price today?
One share of Summit Therapeutics PLC stock can currently be purchased for approximately GBX 182.50.
MarketBeat Community Rating for Summit Therapeutics PLC (LON SUMM)MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Summit Therapeutics PLC (LON:SUMM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Consensus Price Target History for Summit Therapeutics PLC (LON:SUMM)
Analysts' Ratings History for Summit Therapeutics PLC (LON:SUMM)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 6/15/2017 | N+1 Singer | Reiterated Rating | corporate | |  |
(Data available from 10/23/2015 forward)
Earnings History for Summit Therapeutics PLC (LON:SUMM)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Summit Therapeutics PLC (LON:SUMM)Current Year EPS Consensus Estimate: $-38.45 EPS
Dividend History for Summit Therapeutics PLC (LON:SUMM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Summit Therapeutics PLC (LON:SUMM)Insider Trades by Quarter for Summit Therapeutics PLC (LON:SUMM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/17/2015 | Valerie Andrews | Insider | Buy | 10,500 | GBX 145 | £15,225 | |
(Data available from 1/1/2013 forward)
Headline Trends for Summit Therapeutics PLC (LON:SUMM)
Latest Headlines for Summit Therapeutics PLC (LON:SUMM)
| Source: |
|
Loading headlines, please wait.
Summit Therapeutics PLC (SUMM) Chart for Monday, October, 23, 2017
